High voltage-activated (HVA) Ca^2+^ (Ca~V~) channels convert electrical signals into Ca^2+^ influx that controls myriad essential processes including neuronal communication, muscle contraction, hormone release, and activity-dependent gene transcription ([@r1]). HVA Ca~V~ channels are composed of a pore-forming α~1~- assembled with auxiliary β-, α~2~δ-, and γ-subunits and calmodulin. There are seven α~1~-subunits (Ca~V~1.1 to 1.4 and Ca~V~2.1 to 2.3), four Ca~V~βs (β~1~ to β~4~), and three α~2~δs (α~2~δ1 to α~2~δ3), each with multiple splice variants. Ca~V~α~1~-subunits contain the voltage sensor, selectivity filter, and channel pore, while auxiliary subunits regulate channel properties---Ca~V~βs are obligatory for α~1~-trafficking to the plasma membrane and for modulating channel gating ([@r2]); α~2~δs enhance channel surface trafficking and also modulate channel gating ([@r3]); and calmodulin promotes channel trafficking, enhances basal open probability (*P*~o~), and confers feedback Ca^2+^ regulation of channel gating ([@r4], [@r5]).

Ca~V~ channels are also regulated by various intracellular signaling proteins and posttranslational modifications as a mechanism to control physiology. Pharmacological blockade of Ca~V~1/Ca~V~2 channels is an important treatment strategy for diverse diseases including hypertension, cardiac arrhythmias, chronic pain, and Parkinson's disease ([@r1]). RGK proteins (Gem, Rad, Rem, and Rem2) are small Ras-like G proteins that bind Ca~V~β-subunits and profoundly inhibit all Ca~V~1/Ca~V~2 channels ([@r6][@r7]--[@r8]). Given their properties, RGKs straddle two worlds with respect to their impact on Ca~V~1/Ca~V~2 channels---they are (*i*) potentially powerful physiological regulators by virtue of their capacity to tune intracellular Ca^2+^ signals, and (*ii*) prototype genetically encoded Ca~V~ channel blockers with possible therapeutic and biotechnological applications ([@r9]). Consistent with important physiological roles, Rad knockout mice exhibit increased cardiac Ca~V~1.2 currents and cardiac hypertrophy, while Gem-deficient mice display glucose intolerance and impaired glucose-stimulated insulin release. Regarding their use as potential therapeutics, expression of Gem in the atrioventricular node was effective at electrically uncoupling ventricular excitation from the fibrillating atria in a porcine model of atrial fibrillation ([@r10]). A Rem derivative engineered to selectively target and inhibit caveola-localized Ca~V~ channels effectively inhibited pacing-induced NFATc3-GFP translocation to the nucleus in adult feline ventricular cardiomyocytes, without affecting excitation--contraction coupling ([@r11]).

A major limitation for the use of RGKs as genetically encoded Ca~V~ channel blockers involves their lack of selectivity for particular Ca~V~1/Ca~V~2 isoforms. Rem inhibits Ca~V~1.2 channels using multiple mechanisms including reduced channel surface density, diminished *P*~o~, and partial immobilization of voltage sensors ([@r12]). At least one of these mechanisms (decreased *P*~o~) involves the simultaneous association of Rem with the auxiliary Ca~V~β-subunit and the plasma membrane ([@r13], [@r14]). This mechanism likely accounts for the indiscriminate nature of RGK inhibition of Ca~V~1/Ca~V~2 channels, since all four RGKs bind Ca~V~β-subunits and the plasma membrane, and Ca~V~βs are obligatory for forming functional channels. Beyond the β-binding mechanism, we previously showed that Rem can also inhibit Ca~V~1.2 channels by directly binding to the pore-forming α~1C~-subunit ([@r15]). Potentially, such an α~1~-subunit--dependent mechanism could be exploited to develop genetically encoded Ca~V~1/Ca~V~2 isoform-selective inhibitors. Several outstanding questions need to be addressed to realize this potential. Does Rem inhibit other Ca~V~1/Ca~V~2 channels beyond Ca~V~1.2 in a β-binding--independent manner? Do other RGKs beyond Rem inhibit Ca~V~1/Ca~V~2 channel isoforms in a β-binding--independent manner? Are both β-binding--dependent and β-binding--independent mechanisms of RGK inhibition of particular Ca~V~1/Ca~V~2 channels prevalent in native excitable cells? If so, do the two modes of inhibition display physiologically meaningful differences?

Here, focusing on four Ca~V~ channels (Ca~V~1.2, Ca~V~1.3, Ca~V~2.1, and Ca~V~2.2), we show that Rem uniquely blocks Ca~V~1.2 using a β-binding--independent mechanism. Consistent with this finding, a mutant Rem that cannot bind β (Rem\[R200A/L227A\]) selectively blocked Ca~V~1.2, with no effect on the closely related Ca~V~1.3 channel. Further, Rad inhibited Ca~V~1.2 and Ca~V~2.2 (but not Ca~V~1.3 or Ca~V~2.1) channels via a β-binding--independent mechanism. Accordingly, a β-binding--deficient Rad mutant (Rad\[R208A/L235A\]) effectively blocked Ca~V~1.2/Ca~V~2.2, but not Ca~V~1.3/Ca~V~2.1, channels. Both Rem\[R200A/L227A\] and Rad\[R208A/L235A\] strongly inhibited endogenous Ca~V~1.2 channels in adult ventricular cardiomyocytes. Finally, Rem\[R200A/L227A\] and Rad\[R208A/L235A\], but not Gem\[R196A/V223A\], inhibited HVA Ca~V~ channels in somatosensory dorsal root ganglion (DRG) neurons, albeit with different magnitudes reflecting their selectivity for either Ca~V~1.2 alone or Ca~V~1.2/Ca~V~2.2, respectively. Altogether, we have exploited latent β-binding--independent inhibition of Ca~V~1.2 and Ca~V~1.2/Ca~V~2.2 channels by Rem and Rad, respectively, to engineer genetically encoded isoform-selective Ca~V~ channel blockers.

Results {#s1}
=======

Differential Prevalence of β-Binding--Dependent and β-Binding--Independent Rem Inhibition Across Distinct Ca~V~1/Ca~V~2 Channels. {#s2}
---------------------------------------------------------------------------------------------------------------------------------

We profiled β-binding--dependent (BBD) and β-binding--independent (BBI) Rem inhibition of Ca~V~ channels by reconstituting distinct pore-forming α~1~-subunits with either wild-type β~2a~ or a mutant β~2a~ (β~2a,TM~) that does not bind RGKs. HEK293 cells expressing α~1C~ + β~2a~ expressed robust Ba^2+^ currents (*I*~Ba~) that were virtually eliminated when Rem was coexpressed ([Fig. 1 *A* and *B*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Similarly, cells expressing α~1C~ + β~2a,TM~ displayed *I*~Ba~ that was significantly inhibited by Rem ([Fig. 1 *A* and *B*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)), indicating the incidence of both BBD and BBI Rem inhibition of Ca~V~1.2 channels. These results confirm our previous report that both BBD and BBI mechanisms contribute to Rem inhibition of Ca~V~1.2 ([@r15]). *I*~Ba~ influx through reconstituted Ca~V~1.3 channels (α~1D~ + β~2a~) was eliminated by Rem. However, Ca~V~1.3 channels reconstituted with α~1D~ + β~2a,TM~ were refractory to Rem ([Fig. 1 *C* and *D*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)), indicating the absence of BBI inhibition, and revealing a fundamental difference from Ca~V~1.2. Similar to Ca~V~1.3, Ca~V~2.1 ([Fig. 1 *E* and *F*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)) and Ca~V~2.2 ([Fig. 1 *G* and *H*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)) channels were inhibited by Rem only when reconstituted with WT β~2a~, but not β~2a,TM~, a modulation profile consistent with exclusively BBD inhibition.

![Rem uniquely inhibits Ca~V~1.2 using both β-binding--dependent and β-binding--independent mechanisms. (*A*) Exemplar Ca~V~1.2 Ba^2+^ currents elicited from HEK293 cells expressing α~1C~ + β~2a~ ± Rem (columns 1 and 2) or α~1C~ + β~2a,TM~ ± Rem (columns 3 and 4). Ba^2+^ currents were elicited by 25-ms test pulse depolarizations (from −50 to +100 mV in 10-mV increments) from a holding potential of −90 mV. (*B*) Population bar charts showing the impact of Rem on peak *I*~Ba~ from channels reconstituted with either α~1C~ + β~2a~ (*Left*) or α~1C~ + β~2a,TM~ (*Right*). \**P* \< 0.01, Student's unpaired *t* test. (*C* and *D*) Data for Ca~V~1.3 channels reconstituted with either α~1D~ + β~2a~ ± Rem or α~1D~ + β~2a,TM~ ± Rem, same format as *A* and *B*. (*E* and *F*) Data for Ca~V~2.1 channels reconstituted with either α~1A~ + β~2a~ ± Rem or α~1A~ + β~2a,TM~ ± Rem, same format as *A* and *B*. (*G* and *H*) Data for Ca~V~2.2 channels reconstituted with either α~1B~ + β~2a~ ± Rem or α~1B~ + β~2a,TM~ ± Rem, same format as *A* and *B*. Data are means ± SEM.](pnas.1811024115fig01){#fig01}

Engineering a Ca~V~1.2-Selective Inhibitor from Rem. {#s3}
----------------------------------------------------

The finding that BBI Rem inhibition of *I*~Ba~ is a unique property of Ca~V~1.2 suggested the possibility of engineering a Ca~V~1.2-selective genetically encoded inhibitor by generating a Rem mutant that does not bind Ca~V~β. A previous mutagenesis study identified residues in RGKs that were critical for their interaction with Ca~V~βs but did not disrupt their tertiary structure, as evaluated by GTP/GDP binding assays ([@r16]). Based on these findings, we introduced two point mutations (R200A, L227A) into Rem and used FRET to evaluate the association of Rem\[R200A/L227A\] with Ca~V~β ([Fig. 2*A*](#fig02){ref-type="fig"}). HEK293 cells coexpressing CFP-WT Rem + YFP-β~3~ displayed a significantly elevated FRET (FRET efficiency 0.188 ± 0.006, *n* = 127) compared with negative control cells expressing CFP-FRB + β~3~-YFP (FRET efficiency 0.046 ± 0.002, *n* = 126) ([Fig. 2*B*](#fig02){ref-type="fig"}), consistent with well-known Rem--Ca~V~β interaction ([@r6], [@r7]). By comparison, cells coexpressing CFP-Rem\[R200A/L227A\] + β~3~-YFP displayed a markedly lower FRET (FRET efficiency 0.058 ± 0.002, *n* = 138) that did not differ from control cells, consistent with reduced protein interaction ([Fig. 2*B*](#fig02){ref-type="fig"}). Additional insights into the relative affinities of Rem and Rem\[R200A/L227A\] for Ca~V~β~3~ was provided from binding analyses of FRET efficiency vs. *A*~free~ scatterplots ([Fig. 2*C*](#fig02){ref-type="fig"}), which indicated a fivefold decreased affinity of Rem\[R200A/L227A\] for Ca~V~β~3~ compared with WT Rem ([Fig. 2*C*](#fig02){ref-type="fig"}).

![Rem\[R200A/L227A\] does not bind Ca~V~β and selectively inhibits Ca~V~1.2. (*A*) Crystal structure of Rem G domain with residues R200 and L227 highlighted. (*B*) FRET efficiency measurements in HEK293 cells coexpressing CFP-FRB + β~3~-YFP (control), CFP-Rem + β~3~-YFP, or CFP-Rem\[R200A/L227A\] + β~3~-YFP. Data are means ± SEM. \**P* \< 0.01, one-way ANOVA. (*C*) Binding-curve analyses of FRET experiments. (*D*) Population *I*~peak~--*V* plots for cells expressing α~1C~ + β~2a~ (black squares; *n* = 9), α~1C~ + β~2a~ + Rem\[L200A/L227A\] (red squares; *n* = 10); α~1D~ + β~2a~ (black circles; *n* = 11), α~1D~ + β~2a~ + Rem\[L200A/L227A\] (red circles; *n* = 13); α~1A~ + β~2a~ (black triangles; *n* = 10), α~1A~ + β~2a~ + Rem\[L200A/L227A\] (red triangles; *n* = 12); and α~1B~ + β~2a~ (black diamonds; *n* = 11), α~1B~ + β~2a~ + Rem\[L200A/L227A\] (red diamonds; *n* = 12). \**P* \< 0.05, Student's *t* test. (*E*) Exemplar cultured adult cardiomyocytes expressing GFP (*Top*) or CFP-Rem\[L200A/L227A\] (*Bottom*). (*F*) Representative Ba^2+^ currents from adult guinea pig ventricular cardiomyocytes expressing either GFP (*Left*; control) or CFP-Rem\[L200A/L227A\] (*Right*). (*G*) Population *I*~peak~--*V* plots for cardiomyocytes expressing GFP (black squares; *n* = 8) or CFP-Rem\[L200A/L227A\] (red triangles; *n* = 10).](pnas.1811024115fig02){#fig02}

We next determined whether Rem\[R200A/L227A\] would function as a Ca~V~1.2-selective inhibitor as hypothesized. Indeed, HEK293 cells coexpressing recombinant Ca~V~1.2 (α~1C~ + β~2a~) channels and Rem\[R200A/L227A\] displayed significantly lower *I*~Ba~ compared with control cells expressing Ca~V~1.2 alone ([Fig. 2*D*](#fig02){ref-type="fig"}; *I*~peak,10mV~ = 62.3 ± 14.3 pA/pF, *n* = 9 for α~1C~ + β~2a~ compared with *I*~peak,10mV~ = 24.9 ± 4.9 pA/pF, *n* = 10 for α~1C~ + β~2a~ + Rem\[R200A/L227A\]; *P* = 0.0194, Student's *t* test; [*SI Appendix*, Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). In sharp contrast, recombinant Ca~V~1.3, Ca~V~2.1, and Ca~V~2.2 were refractory to Rem\[R200A/L227A\] ([Fig. 2*D*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)), consistent with this engineered protein being a Ca~V~1.2-selective blocker. The finding that Ca~V~2.2 is not inhibited by a β-binding--deficient Rem recapitulates a previous similar finding by Beqollari et al. ([@r17]).

To determine whether Rem\[R200A/L227A\] could inhibit endogenous Ca~V~1.2 channels, we assessed its efficacy in blocking *I*~Ba~ conducted through native Ca~V~1.2 channels in guinea pig ventricular cardiomyocytes. We generated adenovirus enabling robust expression of YFP-Rem\[R200A/L227A\] ([Fig. 2*E*](#fig02){ref-type="fig"}). Compared with control cells expressing GFP, cardiomyocytes expressing YFP-Rem\[R200A/L227A\] displayed a significantly reduced *I*~Ba~ at all test voltages ([Fig. 2 *F* and *G*](#fig02){ref-type="fig"}; *I*~peak,0mV~ = 22.6 ± 4.6 pA/pF, *n* = 8 for GFP compared with *I*~peak,0mV~ = 9.1 ± 2.3 pA/pF, *n* = 10, for YFP-Rem\[R200A/L227A\]), thus demonstrating BBI Rem inhibition of endogenous Ca~V~1.2 channels in the heart.

Prevalence of BBD and BBI RGK Inhibition Across the Ca~V~1/Ca~V~2 Channel Family. {#s4}
---------------------------------------------------------------------------------

We wondered whether other RGKs display BBI inhibition of Ca~V~1/Ca~V~2 channels that could be similarly exploited to generate selective genetically encoded inhibitors for Ca~V~ channels (GECCIs). We profiled the occurrence of BBD and BBI inhibition across RGKs and Ca~V~1/Ca~V~2 channels by assessing the impact of Gem, Rad, and Rem2 on recombinant Ca~V~ channels reconstituted with either WT β~2a~ or β~2a,TM~ ([Fig. 3*A*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Ca~V~1.3 channels reconstituted with WT β~2a~ (α~1D~ + β~2a~) were uniformly inhibited by Gem, Rad, and Rem2, respectively ([*SI Appendix*, Fig. S3*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). By contrast, these three RGKs had no impact on *I*~Ba~ influx through α~1D~ + β~2a,TM~ channels ([*SI Appendix*, Fig. S3*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Together, these results indicate that all RGKs inhibit Ca~V~1.3 channels solely through a BBD mechanism. We obtained virtually identical results with reconstituted Ca~V~2.1 channels---α~1A~ + β~2a~ channels were inhibited by Gem, Rad and Rem2, whereas α~1A~ + β~2a,TM~ channels were refractory to these RGKs ([*SI Appendix*, Fig. S3*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Hence, Ca~V~2.1 channels also display exclusively BBD RGK inhibition. The finding that Rem2 inhibits Ca~V~2.1 in a solely BBD manner agrees with a previous result showing that Rem2 abolishes current through Ca~V~2.1 channels reconstituted with WT β~4~ but not a mutant β~4~ lacking the capacity to bind Rem2 ([@r18]). Our finding that Gem requires binding to Ca~V~β to decrease Ca~V~2.1 is in disagreement with a previous report that Gem binding to Ca~V~β~3~ was not necessary for its capacity to inhibit Ca~V~2.1 current ([@r19]). The reasons for this discrepancy are unclear, though one possibility is the intrinsic differences between *Xenopus* oocytes (used in the previous study) and the mammalian cells used here. As expected, wild-type Ca~V~2.2 channels (α~1B~ + β~2a~) were robustly inhibited by Gem, Rad, and Rem2, respectively. Interestingly, while channels reconstituted with α~1B~ + β~2a,TM~ were unaffected by Gem and Rem2, they were significantly inhibited by Rad ([Fig. 3*B*](#fig03){ref-type="fig"}). Therefore, Rad uniquely mediates both BBD and BBI inhibition of Ca~V~2.2 channels. We previously reported that Rad (but not Gem or Rem2) also supports BBD and BBI inhibition of Ca~V~1.2 ([@r15]). Together, these reports suggested that eliminating Rad binding to Ca~V~β would generate a selective inhibitor of Ca~V~1.2/Ca~V~2.2 channels.

![Prevalence of β-binding--dependent and β-binding--independent RGK inhibition of *I*~Ba~ in Ca~V~2.2 channels. (*A*) Schematic of HVA Ca~V~ channel pore-forming α~1~-subunit binding to β~2a~ or β~2a,TM~ with putative binding sites responsible for β-binding--dependent (solid arrow) and β-binding--independent (dashed arrows) RGK inhibition of current. (*B*) Bar charts showing impact of Gem, Rad, and Rem2 on Ca~V~2.2 channels reconstituted with either α~1B~ + β~2a~ (*Left*) or α~1B~ + β~2a,TM~ (*Right*). Data are means ± SEM. \**P* \< 0.05 compared with control, one-way ANOVA.](pnas.1811024115fig03){#fig03}

Engineering a Ca~V~1.2- and Ca~V~2.2-Selective Inhibitor from Rad. {#s5}
------------------------------------------------------------------

Using an approach similar to the generation of Rem\[R200A/L227A\], we introduced equivalent mutations in Rad to create Rad\[R208A/L235A\]. Three-cube FRET experiments confirmed that cells expressing CFP-Rad\[R208A/L235A\] + YFP-β~3~ showed lower FRET efficiency (0.051 ± 0.002, *n* = 142) compared with CFP-Rad + YFP-β~3~ (0.123 ± 0.004, *n* = 174) ([Fig. 4*B*](#fig04){ref-type="fig"}). Binding-curve analyses indicated an eightfold decrease in affinity of CFP-Rad\[R208A/L235A\] for YFP-β~3~ compared with CFP-Rad ([Fig. 4*C*](#fig04){ref-type="fig"}). As predicted, Rad\[R208A/L235A\] significantly inhibited currents through recombinant Ca~V~1.2 (α~1C~ + β~2a~) and Ca~V~2.2 (α~1B~ + β~2a~) channels but had no impact on either Ca~V~1.3 (α~1D~ + β~2a~) or Ca~V~2.1 (α~1A~ + β~2a~) channels ([Fig. 4*D*](#fig04){ref-type="fig"} and [*SI Appendix*, Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Hence, Rad\[R208A/L235A\] is a Ca~V~1.2/Ca~V~2.2-selective inhibitor. When expressed in guinea pig ventricular cardiomyocytes, Rad\[R208A/L235A\] inhibited endogenous Ca~V~1.2 channels to almost the same extent as WT Rad ([Fig. 4 *E* and *F*](#fig04){ref-type="fig"}), revealing a strong BBI Rad inhibition of Ca~V~1.2 in the heart. It was previously shown that Rad-inhibited Ca~V~1.2 channels are not up-regulated by activated protein kinase A (PKA) ([@r20]). We found that *I*~Ba~ through ventricular Ca~V~1.2 channels inhibited by Rad\[R208A/L235A\] was robustly increased by 1 μM forskolin, in sharp contrast to the lack of modulation observed with WT Rad-inhibited channels ([Fig. 4 *G* and *H*](#fig04){ref-type="fig"} and [*SI Appendix*, Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Hence, cardiac Ca~V~1.2 channels undergoing either BBD or BBI Rad inhibition display fundamental differences in their sensitivity to PKA regulation. A caveat here is we cannot discount a contribution of Ca~V~1.2 channels which are not bound to Rad\[R208A/L235A\] to the observed forskolin-induced increase in *I*~Ba~. However, the finding that Rad\[R208A/L235A\] inhibits cardiac Ca~V~1.2 to almost the same extent as WT Rad ([Fig. 4 *E* and *F*](#fig04){ref-type="fig"}) suggests Rad\[R208A/L235A\]-bound channels predominate over unbound channels, and is consistent with the interpretation that Ca~V~1.2 channels undergoing BBI Rad inhibition are up-regulated by PKA activation.

![Rad\[R208A/L235A\] does not bind Ca~V~β and selectively inhibits Ca~V~1.2 and Ca~V~2.2 channels. (*A*) Crystal structure of Rad G domain with residues R208 and L235 highlighted. (*B*) FRET efficiency measurements in HEK293 cells coexpressing CFP-FRB + β~3~-YFP (control), CFP-Rad + β~3~-YFP, or CFP-Rad\[R208A/L235A\] + β~3~-YFP. Data are means ± SEM. \**P* \< 0.01, one-way ANOVA. (*C*) Binding-curve analyses of FRET experiments. (*D*) Population *I*~peak~--*V* plots for cells expressing α~1C~ + β~2a~ (black squares; *n* = 11), α~1C~ + β~2a~ + Rad\[R208A/L235A\] (red squares; *n* = 10); α~1D~ + β~2a~ (black circles; *n* = 10), α~1D~ + β~2a~ + Rad\[R208A/L235A\] (red circles; *n* = 13); α~1A~ + β~2a~ (black triangles; *n* = 10), α~1A~ + β~2a~ + Rad\[R208A/L235A\] (red triangles; *n* = 11); and α~1B~ + β~2a~ (black diamonds; *n* = 10), α~1B~ + β~2a~ + Rad\[R208A/L235A\] (red diamonds; *n* = 14). *P* \< 0.05, Student's *t* test. (*E*) Exemplar Ba^2+^ currents from cultured adult guinea pig ventricular cardiomyocytes expressing Rad (*Top*) and Rad\[R208A/L235A\] (*Bottom*). (*F*) Population *I*~peak~--*V* for cardiomyocytes expressing either CFP-Rad (red squares; *n* = 4) or CFP-Rad\[R208A/L235A\] (blue squares; *n* = 8). Dotted line is mean current density for control cardiomyocytes expressing GFP, reproduced from [Fig. 2*G*](#fig02){ref-type="fig"}. (*G*) Exemplar currents (*Top*) and diary plot (*Bottom*) showing the impact of 1 μM forskolin on *I*~Ba~ in cardiomyocytes expressing CFP-Rad\[R208A/L235A\]. (*H*) Bar chart showing differential impact of forskolin in up-regulating Ca~V~1.2 *I*~Ba~ in cardiomyocytes expressing CFP-Rad or CFP-Rad\[R208A/L235A\]. Data are means ± SEM.](pnas.1811024115fig04){#fig04}

Rem\[R200A/L227A\] and Rad\[R208A/L235A\] Inhibit HVA Ca~V~ Channels in Dorsal Root Ganglion Neurons. {#s6}
-----------------------------------------------------------------------------------------------------

Finally, we determined the performance of Rem\[R200A/L227A\] and Rad\[R208A/L235A\] as Ca~V~ channel inhibitors in primary cells with a complex expression of multiple Ca~V~ channel types. We chose dorsal root ganglion neurons which express multiple HVA Ca~V~1/Ca~V~2 channels as well as low voltage-activated (LVA) Ca~V~3.2 channels. Mouse DRG neurons express mostly Ca~V~2.1 and Ca~V~2.2, with a smaller contribution of Ca~V~1.2 and Ca~V~2.3 channels ([@r21]). We used adenoviral vectors to robustly express GFP (control) or CFP-tagged RGKs in cultured mouse DRG neurons ([Fig. 5*A*](#fig05){ref-type="fig"}). In control cells, a ramp protocol elicited two components of *I*~Ba~, reflecting currents through LVA and HVA Ca~V~ channels, respectively. Overexpressing WT Rad essentially eliminated the HVA current component while leaving the LVA element intact ([Fig. 5*B*](#fig05){ref-type="fig"}). We further assessed the impact of various WT and mutant RGKs on the HVA Ca~V~ channel currents using step depolarizations. For these experiments, LVA Ca~V~ channel currents were eliminated by 5 μM mibefradil and a −50-mV holding potential. Control DRG neurons displayed HVA *I*~Ba~ currents which were dramatically reduced by WT Rad ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"}; *I*~peak,−10mV~ = −76.5 ± 13.8 pA/pF, *n* = 10 for GFP compared with *I*~peak,−10mV~ = −3.5 ± 1.3 pA/pF, *n* = 19 for CFP-Rad; [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). DRG neurons expressing CFP-Rad\[R208A/L235A\] showed a significant 62% decrease in HVA *I*~Ba~ compared with control ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"}; *I*~peak,−10mV~ = −29.8 ± 5.8 pA/pF, *n* = 13; [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Similar to WT Rad, DRG neurons expressing either CFP-Rem or CFP-Gem showed a dramatically reduced HVA *I*~Ba~ amplitude ([Fig. 5*D*](#fig05){ref-type="fig"}; *I*~peak,−10mV~ = −8.7 ± 3.8 pA/pF, *n* = 8 for CFP-Rem, and *I*~peak,−10mV~ = −4.8 ± 0.9 pA/pF, *n* = 4 for CFP-Gem; [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Expressing CFP-Rem\[R200A/L227A\] depressed HVA *I*~Ba~ by 25% compared with control ([Fig. 5*D*](#fig05){ref-type="fig"}; *I*~peak,−10mV~ = −56.5 ± 6.6 pA/pF, *n* = 13; [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)), substantially less than the reduction observed with CFP-Rad\[R208A/L235A\]. By contrast, Gem\[R196A/V223A\] had no impact on HVA *I*~Ba~ in DRG neurons ([Fig. 5*D*](#fig05){ref-type="fig"}; *I*~peak,−10mV~ = −74.5 ± 15.4 pA/pF, *n* = 12; [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental)). Overall, the rank order of inhibition of HVA *I*~Ba~ by these mutant RGKs is consistent with the notion that CFP-Rad\[R208A/L235A\] inhibits both Ca~V~1.2 and Ca~V~2.2, CFP-Rem\[R200A/L227A\] inhibits only Ca~V~1.2, and Gem\[R196A/V223A\] is inert against HVA Ca~V~ channels.

![Differential block of high voltage-activated Ca~V~ channel currents in DRG neurons by WT and mutant RGK proteins. (*A*) Representative images of cultured DRG neurons expressing GFP, CFP-Rad, or CFP-Rad\[R208A/L235A\]. (*B*) Exemplar *I*~Ba~ waveforms elicited by voltage-ramp protocols in DRG neurons expressing GFP (*Left*) or CFP-Rad (*Right*). (*C*) Exemplar family of HVA *I*~Ba~ from DRG neurons expressing GFP (*Left*), CFP-Rad (*Middle*), or CFP-Rad\[208A/L235A\] (*Right*). Currents were elicited from a holding potential of −50 mV and in the presence of 1 μM mibefradil to eliminate LVA T-type currents. (*D*) Bar chart showing the relative impact of distinct WT and β-binding--deficient mutant RGKs on HVA Ca~V~1/Ca~V~2 channel currents in cultured DRG neurons. Data are means ± SEM. \**P* \< 0.05, one-way ANOVA and post hoc Bonferroni test.](pnas.1811024115fig05){#fig05}

Discussion {#s7}
==========

Pharmacological blockade of distinct Ca~V~1/Ca~V~2 channel types is an important actual or potential therapy for many diseases, including hypertension (Ca~V~1.2), angina (Ca~V~1.2), cardiac arrhythmias (Ca~V~1.2), chronic pain (Ca~V~2.2), stroke (Ca~V~2), and Parkinson's disease (Ca~V~1.3) ([@r1], [@r22], [@r23]). Ca~V~1 channels are effectively blocked by dihydropyridines, benzothiazepines, and phenylalkylamines, while Ca~V~2 channels are inhibited by various animal venoms: ω-agatoxin IVA (Ca~V~2.1), ω-conotoxins GVIA and MVIIA (Ca~V~2.2), and SNX-482 (Ca~V~2.3) ([@r24]). Prialt (ziconotide), a blocker of Ca~V~2.2 derived from a marine snail conotoxin, is Food and Drug Administration-approved for the treatment of chronic pain ([@r25]). The use of small-molecule Ca~V~1/Ca~V~2 channel blockers is mainly limited by two factors. First, Ca~V~1/Ca~V~2 expression in many types of excitable cells risks prohibitive off-target effects. Second, due to a high degree of similarity among pore-forming α~1~-subunits (e.g., the L-type channels, Ca~V~1.1 to Ca~V~1.4), currently available small-molecule blockers may not effectively distinguish between Ca~V~ channels of the same class. Difficulties encountered in developing Ca~V~1.3-selective blockers as a potential treatment for Parkinson's disease exemplify these challenges ([@r26], [@r27]). Efficacy of such a treatment approach was suggested by reports that the reliance of substantia nigra neurons on Ca~V~1.3 for pacemaking made them sensitive to Ca^2+^ overload and vulnerable to cell death which drives the development of Parkinson's disease ([@r28], [@r29]). Epidemiological studies suggest indeed some beneficial effects of L-type calcium channel (LTCC) blockers in Parkinson's disease ([@r30]). However, because the currently available LTCC blockers are not selective for Ca~V~1.3, off-target effects (e.g., on cardiovascular Ca~V~1.2 channels) risk serious side effects such as hypotension, significantly narrowing the therapeutic window ([@r31]).

Genetically encoded Ca~V~ channel blockers could offer an alternative solution without the above-mentioned drawbacks of small-molecule inhibitors. Off-target effects might be avoided by restricted expression in target tissues or defined cell populations ([@r9], [@r10]). RGKs are promising candidates for such an alternative treatment approach, given their potency as Ca~V~ channel blockers. Their potential usefulness is twofold: (*i*) as endogenous GECCIs for therapeutic or biotechnological applications, and (*ii*) as natural prototypes that can help inform strategies to design novel GECCIs for targeted applications in diseases involving excitable cells. Regarding the former, the indiscriminate nature of RGK inhibition of all Ca~V~1/Ca~V~2 channels represents a potential obstacle for some applications. We tested here whether selectivity for particular Ca~V~1/Ca~V~2 isoforms could be engineered into RGKs. Based on the intuition that the indiscriminate manner with which RGKs inhibit all Ca~V~1/Ca~V~2 channel types is a consequence of their binding to auxiliary Ca~V~β-subunits, we mutated RGKs to eliminate their capacity of binding to Ca~V~β. This simple maneuver revealed Rem\[R200A/L227A\] as a Ca~V~1.2-selective blocker and Rad\[R208A/L235A\] as a selective inhibitor for Ca~V~1.2/Ca~V~2.2. The selectivity of Rem\[R200A/L227A\] for Ca~V~1.2 over Ca~V~1.3 is noteworthy, given that currently available small-molecule LTCC blockers do not distinguish these channels. Hence, Rem\[R200A/L227A\] could be a valuable tool for differentially blocking Ca~V~1.2- and Ca~V~1.3-mediated signaling in excitable cells, such as many types of neurons, that coexpress both channel types. Similarly, Rad\[R208A/L235A\] could be applied to examine Ca~V~1.2/Ca~V~2.2-dependent signaling pathways. The effectiveness of both Rem\[R200A/L227A\] and Rad\[R208A/L235A\] in blocking HVA Ca~V~ channels in heart cells and DRG neurons demonstrates their utility as selective GECCIs. Additionally, our experiments revealed the existence of BBI mechanisms underlying Rem and Rad inhibition of Ca~V~1/Ca~V~2 channels in excitable cells. This raises the question of the biological significance of BBD versus BBI Ca~V~ channel inhibition by RGKs. Our findings in cardiac myocytes suggest indeed functionally relevant differences between the two inhibitory mechanisms. Cardiac Ca~V~1.2 channels are acutely up-regulated pharmacologically by agonists such as BAY K 8644 or physiological activation of PKA initiated by β-adrenergic agonists. The latter contributes to the fight-or-flight response. Rem-inhibited Ca~V~1.2 channels in heart cells can be overridden by BAY K 8644, indicating that the blocked channels remain at the cell surface ([@r32]). However, both WT Rem- and Rad-inhibited channels are insensitive to PKA-mediated regulation ([@r20], [@r32]). By contrast, we found that Ca~V~1.2 channels inhibited by either Rem\[R200A/L227A\] or Rad\[R208A/L235A\] can be robustly up-regulated by PKA. These results suggest that cardiac Ca~V~1.2 channels inhibited by Rem or Rad through the BBD mechanism are electrically silent, while those inhibited by the BBI pathway are coincidentally activated by membrane depolarization and PKA-mediated phosphorylation. This paradigm could solve the conundrum of how a subset of Ca~V~1.2 channels in heart cells might be reserved for signaling functions other than contraction, given that these channels are voltage-gated and the cardiac sarcolemma is subject to excitation with each heartbeat ([@r33], [@r34]). In this regard, it is noteworthy that GDP-bound Rem and Rad have a lower affinity for Ca~V~β than their GTP-loaded counterparts ([@r35]). We speculate that endogenous Rad toggles between BBD and BBI mechanisms to inhibit cardiac Ca~V~1.2 channels dependent on the G domain being bound to GTP or GDP. Testing this proposition will be an interesting concept for future experiments.

Materials and Methods {#s8}
=====================

Detailed methods are provided in [*SI Appendix*, *Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811024115/-/DCSupplemental).

Cell Culture and Transfection. {#s9}
------------------------------

Low‐passage‐number HEK293 cells were transiently transfected with Ca~V~α (6 μg), Ca~V~β (4 μg), T antigen (2 μg), and RGKs (4 μg) using the calcium‐phosphate precipitation method.

Primary Cell Isolation and Culture. {#s10}
-----------------------------------

Primary cultures of adult guinea pig heart cells and murine DRG neurons were prepared and infected with adenovirus as described ([@r14], [@r36], [@r37]). Procedures were in accordance with the guidelines of the Columbia University Animal Care and Use Committee.

Molecular Biology, Plasmids, and Adenoviral Vectors. {#s11}
----------------------------------------------------

Generation of XFP-tagged RGKs (Rad, Rem, Rem2, and Gem) and β~2a,TM~ has been previously described ([@r12], [@r15]). Adenoviral vectors were generated using the AdEasy XL System (Stratagene) as previously described ([@r38]).

Electrophysiology. {#s12}
------------------

Whole‐cell recordings were carried out at room temperature on HEK293 cells 48 to 72 h after transfection as previously described ([@r12]). Whole-cell currents were recorded from isolated ventricular myocytes as described ([@r36], [@r39]).

Fluorescence Resonance Energy Transfer Imaging. {#s13}
-----------------------------------------------

We used three‐cube FRET to probe protein--protein interactions ([@r35]). Relative *K*~d~ and *E*~max~ values were calculated as previously described ([@r35], [@r40]).
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